Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotechnology company developing precision therapies for kidney diseases using genetics and genomics.
Goldfinch Bio was a clinical-stage biotechnology company founded in 2016 by Third Rock Ventures, based in Cambridge, Massachusetts. It focused on discovering and developing precision therapies for patients with kidney diseases, leveraging genetics, genomics, and multiomics approaches. The company aimed to address significant unmet needs in nephrology, particularly for progressive and rare conditions, by targeting molecular drivers of disease and creating therapies for genetically stratified patient groups. To achieve this, Goldfinch Bio built an inclusive patient registry, integrating genomic and phenotypic data for drug discovery. It successfully raised a total of $214 million in disclosed funding from prominent investors, including Third Rock Ventures, Gilead Sciences, and BlackRock, with scientific co-founders like Peter Mundel and Joseph Bonventre. Despite its innovative strategy, Goldfinch Bio ceased operations in 2023 due to funding challenges.
Goldfinch Biopharma has raised $155.0M across 2 funding rounds.
Goldfinch Biopharma has raised $155.0M in total across 2 funding rounds.
Goldfinch Biopharma has raised $155.0M across 2 funding rounds. Most recently, it raised $100.0M Series B in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 30, 2020 | $100M Series B | JOY Ghosh | Ally Bridge Group, BlackRock, Casdin Capital, Gilead Sciences, Irving Investors, Schroders Capital, Wellington Management, Yonjin Capital | Announced |
| Dec 14, 2016 | $55M Series A | Abbie Celniker | — | Announced |
Goldfinch Biopharma has raised $155.0M in total across 2 funding rounds.
Goldfinch Biopharma's investors include Joy Ghosh, Ally Bridge Group, BlackRock, Casdin Capital, Gilead Sciences, Irving Investors, Schroders Capital, Wellington Management, Yonjin Capital, Abbie Celniker.